Skip to Content

Chugai Extends Shelf Life of Tamiflu

Extension of the Shelf-Life for the Anti-Influenza Virus Drug Tamiflu®Capsules 75

July 01, 2013 (TOKYO) - Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku Tokyo; Chairman & CEO: Osamu Nagayama] (hereafter, “Chugai”) today announced the extension of the shelf-life for the anti-influenza virus drug Tamiflu® Capsules 75 imported from F. Hoffmann-La Roche Ltd. [Head office: Basel, Switzerland; CEO: Severin Schwan] (hereafter, “Roche”) and marketed in Japan by Chugai from the current 7 years to 10 years with the products manufactured in the future.
Chugai decided to extend the shelf-life for Tamiflu® Capsules 75 up to 10 years based on the stability study conducted by Roche.
Future stock of Tamiflu® Dry Syrup 3% (Japan Formulation) will have a shelf-life of 7 years.
Chugai will ensure a stable supply of Tamiflu® in times of future influenza epidemic.

Tamiflu® is trademark of F. Hoffmann-La Roche Ltd., Basel, Switzerland.


Posted: July 2013